NEWS

WIRES

OTHER

Healtheuniverse to Acquire Profitable, Debt Free California Institute of Cosmetic and Reconstructive Surgery

Acquisition to be Accretive to Earnings and Includes CICRS Clinical Database to Advance Evidenced Based Human Clinical Trials for Adult Stem Cell Research

Healtheuniverse Inc. (OTC: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products announced today that it has entered into a Letter Of Intent (LOI) to acquire the assets, operations and clinical database of The California Institute of Cosmetic & Reconstructive Surgery. The acquisition is expected to be accretive to earnings and includes the CICRS clinical database which will prove valuable as the company advances its evidenced based human clinical trials for stem cell applications in the plastic, reconstructive, and cosmetic surgery market. This acquisition is expected to close in the first quarter 2006 subject to customary closing conditions and is another key step to the Company becoming the first to commercialize the use of regenerative medicine and adult stem cells.

Services at the California Institute of Cosmetic & Reconstructive Surgery range from the latest techniques in Cosmetic Surgery to extensive new developments in the field of Reconstructive Surgery. The Institute performs Cosmetic Surgery such as breast augmentation, facelifts, liposuction, and rhinoplasty, as well as extensive Reconstructive Surgery for Breast Cancer, burn victims, trauma victims, chronic wounds, skin cancer, and hand surgery.

Dr. Vipul Dev MD, Chief Executive Officer of Healtheuniverse, Inc. stated, "I am very pleased to expand our organization with the acquisition of CICRS. This acquisition will certainly add revenue and earnings in an area of the market we specialize in and will enable a much faster deployment of our human clinical trials and activities across the U.S. and globally. The plastic and cosmetic surgery industry is at an exciting stage of growth worldwide with interest in advanced non-embryonic stem cell products and services reaching a high point this year. We are clearly at the forefront of this technology."

About HEALTHeUNIVERSE Inc.

HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at http://healtheuniverse.com/

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Distributed by Market Wire